Cora Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.7M Buy
1,420
+77
+6% +$78.7K 0.48% 32
2026
Q1
$1.24M Buy
1,343
+66
+5% +$66.9K 0.41% 36
2025
Q4
$1.37M Buy
1,277
+98
+8% +$93.7K 0.53% 33
2025
Q3
$899K Buy
1,179
+16
+1% +$11.9K 0.38% 42
2025
Q2
$907K Buy
1,163
+130
+13% +$101K 0.4% 40
2025
Q1
$853K Buy
1,033
+21
+2% +$17.5K 0.41% 42
2024
Q4
$781K Buy
1,012
+35
+4% +$29K 0.38% 47
2024
Q3
$866K Buy
977
+36
+4% +$32.4K 0.43% 45
2024
Q2
$852K Buy
941
+7
+0.7% +$5.6K 0.44% 42
2024
Q1
$726K Sell
934
-62
-6% -$44.1K 0.39% 47
2023
Q4
$580K Sell
996
-2
-0.2% -$1.17K 0.34% 49
2023
Q3
$536K Sell
998
-112
-10% -$57.7K 0.36% 49
2023
Q2
$521K Buy
1,110
+154
+16% +$64.6K 0.35% 53
2023
Q1
$328K Buy
956
+26
+3% +$8.77K 0.24% 56
2022
Q4
$340K Buy
+930
New +$330K 0.23% 51

Other funds holding LLY

Cora Capital Advisors's LLY Position: Q2 2026 in Review

Cora Capital Advisors increased its Eli Lilly (LLY) stake by 5.7% in Q2 2026, buying an estimated $78.7K and bringing the position to 1,420 shares worth $1.7M. The position accounts for 0.48% of the portfolio, ranked #32.

Cora Capital Advisors first reported a position in LLY in Q4 2022 and has held it in 15 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cora Capital Advisors held 1,420 shares of Eli Lilly worth $1.7M as of Q2 2026.
  • Cora Capital Advisors bought 77 Eli Lilly shares in Q2 2026, an estimated $78.7K.
  • Eli Lilly made up 0.48% of Cora Capital Advisors's portfolio in Q2 2026, its #32 holding.
  • Cora Capital Advisors first reported a position in Eli Lilly in Q4 2022 and has held it in 15 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cora Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.